{
    "organizations": [],
    "uuid": "1f8f6288c2eb249c8dd844e64a74747c6a7bb980",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-zealand-pharma-fy-net-loss-at-dkk/brief-zealand-pharma-fy-net-loss-at-dkk-272-3-million-idUSFWN1QP0L9",
    "ord_in_thread": 0,
    "title": "BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 7 (Reuters) - ZEALAND PHARMA A/S:\n* FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO\n* NO DIVIDEND HAS BEEN PROPOSED FOR 2017 * FOR 2018, ZEALAND EXPECTS A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.‍​\n* NET OPERATING EXPENSES IN 2018 ARE EXPECTED TO BE WITHIN THE DKK 475-495 MILLION RANGE.‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-07T22:06:00.000+02:00",
    "crawled": "2018-03-08T17:11:57.030+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "zealand",
        "pharma",
        "fy",
        "revenue",
        "dkk",
        "million",
        "versus",
        "dkk",
        "million",
        "year",
        "ago",
        "dividend",
        "proposed",
        "zealand",
        "expects",
        "continued",
        "increase",
        "royalty",
        "payment",
        "net",
        "operating",
        "expense",
        "expected",
        "within",
        "dkk",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}